Clinical trials
Purpura, Thrombocytopenic, Idiopathic trials in China with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
51 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 1 |
| 2014 | 2 |
| 2016 | 3 |
| 2017 | 6 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 6 |
| 2021 | 9 |
| 2022 | 10 |
| 2023 | 7 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 51 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Peking University People's Hospital | 24 |
| Shandong University | 15 |
| Institute of Hematology & Blood Diseases Hospital, China | 3 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2 |
| Beijing InnoCare Pharma Tech Co., Ltd. | 1 |
| Fujian Medical University Union Hospital | 1 |
| Jiangsu HengRui Medicine Co., Ltd. | 1 |
| Peking Union Medical College | 1 |
| Peking Union Medical College Hospital | 1 |
| Qidong Gaitianli Medicines Co., Ltd | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Purpura, Thrombocytopenic, Idiopathic | 51 |
| Thrombocytopenia | 4 |
| Lupus Erythematosus, Systemic | 2 |
| Anemia, Aplastic | 1 |
| Blood Coagulation Disorders | 1 |
| Bronchiolitis Obliterans Syndrome | 1 |
| Connective Tissue Diseases | 1 |
| Lupus Nephritis | 1 |
| Lymphoma, Follicular | 1 |
| Purpura | 1 |
Trials
Showing 1 to 25 of 51. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.